Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers

NCT ID: NCT03383211

Last Updated: 2021-10-20

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 125 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-06-16
• Study Completion Date: 2021-06-30

Brief Summary

Maternal infections affect the basal immune status of neonates. One of the possible mechanism is the fetomaternal microchimerism, in which some cells and active substances are exchanged bi-directionally between maternal and fetal circulation through placenta. Even in the absence of a direct (vertical) transmission of pathogens to fetuses, certain infections make the neonates more prone to allergies and some adverse events of early vaccinations. We postulate that the basal immune status of neonates born to HIV and LTBI infected mothers is primed by gestational exposure to immunological active molecules, which could results in an altered response to early BCG vaccination. Transcripts expression identified by RNA sequencing are compared between sets of mother-child and their respective umbilical cord blood, and between groups of infected and non-infected pairs.

Detailed Description

The study is comparing the transcriptomic profiles of maternal peripheral blood with those of the corresponding umbilical cord blood and neonatal peripheral blood pre- and post-BCG vaccination.

For RNA sequencing, the samples are collected in Tempus RNA Blood tubes at 5 time-points (TP): maternal peripheral blood at the time of initial diagnosis with HIV (first OBGYN consultation @ 12-16 weeks of pregnancy - TP1); repeated HIV test in 3rd trimester of pregnancy (34-36 weeks- TP2); umbilical cord blood (after delivery and ligation- TP3); neonates (24 hours after birth and after HBV vaccination, prior to BCG vaccination- TP4); and neonates (7 days after BCG vaccination- TP5).

As an indicator of the inflammatory status, the peripheral blood samples collected at the same TP are stained for serological markers of inflammation, exhaustion, maturation and activation.

An advanced bioinformatics analysis examines the immune-associated transcripts in RNAseq samples to assess the V(D)J recombination of T-cell and B-cell receptors along with immune-associated SNPs.

The main goal of the study is to identify in umbilical cord blood the genomic biomarkers of the neonatal basal immune status for guiding an optimal BCG immunization protocol for such neonates and to avoid potential adverse events after vaccination.

Conditions

HIV Infections; Neonatal Infection; LTBI - Latent Tuberculosis Infection; Immune Tolerance

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

HIV+

Pregnant women diagnosed with HIV infection during pregnancy. No intervention beyond the standard care provided for such cohort.

RNAseq

Intervention Type: OTHER

Transcriptome profiling of peripheral blood using RNA sequencing technology

LTBI

Pregnant women diagnosed with Latent form of TB infection (LTBI). No intervention beyond the standard of care provided for such cohort.

RNAseq

Intervention Type: OTHER

Transcriptome profiling of peripheral blood using RNA sequencing technology

HV+/LTBI

Pregnant women diagnosed with HIV and LTBI co-infection. No intervention beyond the standard of care provided for such cohort.

RNAseq

Intervention Type: OTHER

Transcriptome profiling of peripheral blood using RNA sequencing technology

Healthy Control

Healthy pregnant women without HIV or LTBI. No intervention beyond the standard of care provided for such cohort.

RNAseq

Intervention Type: OTHER

Transcriptome profiling of peripheral blood using RNA sequencing technology

Interventions

RNAseq

Transcriptome profiling of peripheral blood using RNA sequencing technology

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

Pregnant women, 18-45 years old, capable of reading and understanding the informed consent and the purpose of the study The newborns of the enrolled pregnant women. Women of reproductive age with or without HIV and LTBI infections

Exclusion Criteria

Pregnant women younger than 18 years or older than 45 years of age Pregnant women and infants with known genetic abnormalities, including primary immunodeficiencies; or receiving immunosuppressive therapy; Infants infected in utero, perinatally, or neonatally with hepatitis B virus, Treponema pallidum (syphilis), Toxoplasma gondii, rubella virus, cytomegalovirus, or herpes simplex virus.

Pregnant women with known history of alcohol or drug abuse, cancer diagnosis and treatment with chemotherapeutic agents, radiation.

Pregnant women with history of organ transplantation.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Universitatea de Stat de Medicina si Farmacie Nicolae Testemiţanu

OTHER

Sponsor Role: collaborator

Children's National Research Institute

OTHER

Sponsor Role: collaborator

DC-Center for Aids Research (DC-CFAR)

UNKNOWN

Sponsor Role: collaborator

SeqLL, Inc.

UNKNOWN

Sponsor Role: collaborator

George Washington University

OTHER

Sponsor Role: lead

Responsible Party

Ian Toma, MD, PhD

Associate Research Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Ian Toma, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

George Washington University

Locations

Clinical Municipal Hospital No. 1

Chisinau, , Moldova

National Center for Mother and Child Health

Chisinau, , Moldova

Countries

Moldova

Other Identifiers

GWMDA2017

Identifier Type: -

Identifier Source: org_study_id